158 related articles for article (PubMed ID: 30877214)
21. Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry.
Coulson KA; Reed G; Gilliam BE; Kremer JM; Pepmueller PH
J Clin Rheumatol; 2009 Jun; 15(4):155-60. PubMed ID: 19363452
[TBL] [Abstract][Full Text] [Related]
22. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
[TBL] [Abstract][Full Text] [Related]
23. Risk of fracture in women with glucocorticoid requiring diseases is independent from glucocorticoid use: An analysis on a nation-wide database.
Adami G; Gatti D; Rossini M; Giollo A; Gatti M; Bertoldo F; Bertoldo E; Mudano AS; Saag KG; Viapiana O; Fassio A
Bone; 2024 Feb; 179():116958. PubMed ID: 37949390
[TBL] [Abstract][Full Text] [Related]
24. Guideline-based Treatment of Glucocorticoid-induced Osteoporosis in Patients with Rheumatoid Arthritis: A Retrospective Study with the AORA Registry.
Kawano T; Miyakoshi N; Tsuchie H; Kashiwagura T; Kobayashi M; Aonuma H; Sugimura Y; Shimada Y
Acta Med Okayama; 2021 Dec; 75(6):699-704. PubMed ID: 34955537
[TBL] [Abstract][Full Text] [Related]
25. Management of osteoporosis in rheumatoid arthritis patients.
Hoes JN; Bultink IE; Lems WF
Expert Opin Pharmacother; 2015 Mar; 16(4):559-71. PubMed ID: 25626121
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study.
Karras D; Stoykov I; Lems WF; Langdahl BL; Ljunggren Ö; Barrett A; Walsh JB; Fahrleitner-Pammer A; Rajzbaum G; Jakob F; Marin F
J Rheumatol; 2012 Mar; 39(3):600-9. PubMed ID: 22247365
[TBL] [Abstract][Full Text] [Related]
27. Skeletal complications of rheumatoid arthritis.
Heinlen L; Humphrey MB
Osteoporos Int; 2017 Oct; 28(10):2801-2812. PubMed ID: 28779302
[TBL] [Abstract][Full Text] [Related]
28. Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort.
McKeown E; Bykerk VP; De Leon F; Bonner A; Thorne C; Hitchon CA; Boire G; Haraoui B; Ferland DS; Keystone EC; Pope JE;
Rheumatology (Oxford); 2012 Sep; 51(9):1662-9. PubMed ID: 22539481
[TBL] [Abstract][Full Text] [Related]
29. A comparison of three different guidelines for osteoporosis treatment in patients with rheumatoid arthritis in Korea.
Yoon J; Kwon SR; Lim MJ; Joo K; Moon CG; Jang J; Park W
Korean J Intern Med; 2010 Dec; 25(4):436-46. PubMed ID: 21179283
[TBL] [Abstract][Full Text] [Related]
30. Effects of quality indicator monitoring for glucocorticoid-induced osteoporosis and trends of drug treatment in a Japanese hospital.
Suda M; Suyama Y; Ohde S; Tsuda T; Sawada H; Kishimoto M; Okada M
Int J Rheum Dis; 2018 May; 21(5):975-981. PubMed ID: 29878618
[TBL] [Abstract][Full Text] [Related]
31. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
Kumagai K; Harigane K; Kusayama Y; Tezuka T; Choe H; Inaba Y; Saito T
Osteoporos Int; 2018 Jul; 29(7):1637-1642. PubMed ID: 29574518
[TBL] [Abstract][Full Text] [Related]
32. Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study.
Ebina K; Noguchi T; Hirao M; Hashimoto J; Kaneshiro S; Yukioka M; Yoshikawa H
Osteoporos Int; 2016 Jan; 27(1):351-9. PubMed ID: 26475289
[TBL] [Abstract][Full Text] [Related]
33. Prevalent vertebral fractures and minor vertebral deformities analyzed by vertebral fracture assessment (VFA) increases the risk of incident fractures in postmenopausal women: the FRODOS study.
Kanterewicz E; Puigoriol E; Rodríguez Cros JR; Peris P
Osteoporos Int; 2019 Oct; 30(10):2141-2149. PubMed ID: 31123788
[TBL] [Abstract][Full Text] [Related]
34. Beyond bone mineral density, FRAX-based tailor-made intervention thresholds for therapeutic decision in subjects on glucocorticoid: A nationwide osteoporosis survey.
Yu SF; Chen JF; Chen YC; Lai HM; Ko CH; Chiu WC; Su FM; Hsu CY; Su BY; Wu CH; Cheng TT
Medicine (Baltimore); 2017 Feb; 96(5):e5959. PubMed ID: 28151883
[TBL] [Abstract][Full Text] [Related]
35. Ten-year incidences of self-reported non-vertebral fractures in Japanese patients with rheumatoid arthritis: discrepancy between disease activity control and the incidence of non-vertebral fracture.
Ochi K; Inoue E; Furuya T; Ikari K; Toyama Y; Taniguchi A; Yamanaka H; Momohara S
Osteoporos Int; 2015 Mar; 26(3):961-8. PubMed ID: 25294026
[TBL] [Abstract][Full Text] [Related]
36. Barriers in the management of glucocorticoid-induced osteoporosis.
Guzman-Clark JR; Fang MA; Sehl ME; Traylor L; Hahn TJ
Arthritis Rheum; 2007 Feb; 57(1):140-6. PubMed ID: 17266078
[TBL] [Abstract][Full Text] [Related]
37. [Thyrotoxicosis revelated by bilateral hip fracture].
Sahli H; Cheour E; Metoui L; Frini S; Meddeb N; Sellami S
Tunis Med; 2006 Jun; 84(6):382-4. PubMed ID: 17042215
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of Zoledronic Acid for Treatment of Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.
Wang C
Am J Ther; 2017; 24(5):e544-e552. PubMed ID: 26938765
[TBL] [Abstract][Full Text] [Related]
39. Use of bisphosphonate might be important to improve bone mineral density in patients with rheumatoid arthritis even under tight control: the TOMORROW study.
Tada M; Inui K; Sugioka Y; Mamoto K; Okano T; Anno S; Koike T
Rheumatol Int; 2017 Jun; 37(6):999-1005. PubMed ID: 28405825
[TBL] [Abstract][Full Text] [Related]
40. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society.
Menopause; 2010; 17(1):25-54; quiz 55-6. PubMed ID: 20061894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
